程序性细胞死亡受体1及其配体抑制剂在肝细胞癌治疗中的应用进展

肝细胞癌(HCC)是我国最常见的恶性肿瘤之一,由于缺乏特异性表现,超过一半的患者在初诊时已处于进展期。靶向治疗和系统化疗是进展期HCC的主要治疗方法,疗效有限。近年来,免疫治疗迅速发展。介绍了免疫检查点抑制剂——程序性细胞死亡受体1及其配体(PD-1/PD-L1)抑制剂在HCC治疗中的现状,归纳了多项临床试验的数据结果,分析了单药治疗及联合治疗的安全性及有效性。通过分析表明,免疫治疗已成为全身系统治疗的重要方法之一,尤其是联合治疗可显著提高HCC的疗效,其安全性亦在可控范围内,是未来发展的重要方向。

Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma

Hepatocellular carcinoma(HCC)is one of the most common malignancies in China,and due to the lack of specific symptoms,more than half of these patients are in the advanced stage at the time of initial diagnosis.Targeted therapy and systemic chemotherapies are the main treatment methods for advanced HCC with limited efficacy.In recent years,immunotherapy has been developed rapidly.This article introduces the current status of the immune checkpoint inhibitors,programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors,in the treatment of HCC,summarizes the latest data of several clinical trials,and analyzes the safety and efficacy of monotherapy and combination therapy.The analysis shows that immunotherapy has become one of the important methods for systemic treatment,and combination therapy can significantly improve the outcome of HCC with a manageable safety profile,which is an important direction for future development.